Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here's a Change.com Petition for Aviptadil to be issued an EUA immediately. Everybody on iHub needs to sign it if you believe the EUA should be given now:
http://covidkiller.vip/
I believe dude Diligence was referring to the following video testimonial off of KNOP, an NBC-Nebraskan affiliate, about a survivor given Aviptadil for this Dr.'s own study of the drug at Great Plains Hospital.
https://www.knopnews2.com/video/2020/11/14/aviptadil/
This 'duck test' can also be applied to the Election results.
Since they got 17 Pts enrolled in the last 10 days, I would say so by end of next week or at least before Thanksgiving. Plenty to be thankful for if that's the case.
Your moniker is appropriate if you think that way.
Timing is everything in trading stocks successfully. And being at the right place at the right time.
Not necessarily; It all depends on the # of Pts. that become Eligible IN the Local Area of the Trial Sites.
The FDA official's 'answer' in this Interview on EUAs for Therapeutics is @7:50-9:30.
Basically she says only 5% of the 7,000 odd therapeutics out there being investigated meet the criteria of having "actionable data" (Relief's Aviptadil meets the criteria), and that it's a judgement call based on random trial sample size, statistical power, etc. She does admit there being a lack of coordination on how EUAs are given to Therapeutics, citing how Convalescent Plasma was given EUA without Even having a Trial done!
Thanks very much for this interview!
Isn't going to happen. If the FDA were going to issue the EUA, they would've done it after the last DMC review of the Interim Results. But data results for 102 Pts. isn't nearly enough to make that kind of decision.
Correction: The Relief/NeuroRx Trial Isn't "just a week or so away from...'being finished'"; It's close to completing "Enrollment", which Is Not the same thing as the Trial being finished.
The 165th Patient 'Enrolled' still has to undergo the Study 'Treatment Period' for Covid-19, which I believe is 28 days, before the Trial is finished.
The Swiss & U.S. OTC markets are 2 separate exchanges. Boon is saying that since the Swiss exchange is ahead of us here in the U.S., we'll get a heads-up on how the Relief stock will do.
SWX RLF .34, up 8% Hi-Volume
My bad. Thanks for catching the correct yr. for this article. I need new glasses.
Is that 3.8% difference in reduced mortality considered "statistically significant"? I guess it must be if the FDA gave Remdesavir the EUA.
I'm a recovering Catholic & was only joking. Lol.
RLFTF's volume ended at 6.66M. I hope that's not a bad omen. (Superstition, I know)
{I am interested in how to make it go right. Conversations about the ¨butt-heads” in (name your city or state) who don’t wear masks or social distance misses the point.}
"the 'butt-heads' in (name your city or state) who don’t wear masks or social distance" Does Not "miss the point"; That IS the Whole Point!
Until these "butt-heads" (your words) start cooperating with those of US Who ARE Doing The Right Thing, this country Is Not going to defeat this Pandemic. Until this country starts getting some effective Leadership to show these "butt-heads" that They Need to Do The Right Thing, We Can't defeat Covid-19.
You guys, I've discovered what was behind the big sell-off from the past 10 days, besides the Swiss banker analyst's hit-piece.
{Oct. 23rd
***NeuroRx secures $95M from GEM to fund Ph.3 for its NMDA Depression Drug
After kicking off a Ph.3 Trial testing its NMDA drug in suicidal bipolar depression, NeuroRx has secured access to around ***$95 million to complete the program and fund the manufacturing activities. NY-based ***GEM Global Yield has Committed to *Provide the Capital — *through Purchasing Shares — once NeuroRx gets Listed on a Public Market.}
[*the asterisks are mine]
https://endpts.com/neurorx-secures-95m-to-fund-phiii-for-nmda-depression-drug-trump-revives-science-advisory-council/
So, where will all that $95M come from? Relief's largest investor GEM holding 3/4 Billion shares, that's where!
You can certainly put the blame on the supposed leader of our country for not implementing a national plan or strategy to fight this pandemic. Instead, the Prez just passed the buck to the States to handle it.
Thanks for letting us know about this article! The more press Relief gets, the better for all of us.
Yeh, I saw that and wondered how they could release the data from their Interim results which was reviewed by its DMC.
You guys, I've discovered what was behind the big sell-off from the past 10 days, besides the Swiss banker analyst's hit-piece.
{Oct. 23rd
***NeuroRx secures $95M from GEM to fund Ph.3 for its NMDA Depression Drug
After kicking off a Ph.3 Trial testing its NMDA drug in suicidal bipolar depression, NeuroRx has secured access to around ***$95 million to complete the program and fund the manufacturing activities. NY-based ***GEM Global Yield has Committed to *Provide the Capital — *through Purchasing Shares — once NeuroRx gets Listed on a Public Market.}
[*the asterisks are mine]
https://endpts.com/neurorx-secures-95m-to-fund-phiii-for-nmda-depression-drug-trump-revives-science-advisory-council/
So, where does all that $95M come from? Relief's largest investor GEM holding 3/4 Billion shares.
How would you know that the vast majority of healthy people would not take an effective vaccine if available?
I'm not saying that Vaccines take priority over Therapeutics; that's what the FDA's and medical scientists' focus has been from day one of the pandemic.
Vaccines are different from Therapeutics in how EUAs are given. The Vaccines take priority over Therapeutics.
Something is going on...Stock manipulation?! [from another board]:
Is it logical or is it a mistake to create uncertainty among small shareholders in the meantime via a price push-down?
So that you can take the shares out of their hands at a favorable price before the price inevitably "goes steeply"?
That's what I'm thinking will be the case, but I sincerely hope not.
You don't lose any money unless you sell when the stock is down, which is a pretty foolish thing to do.
I wholeheartedly agree with what you said here, but there has been some improvement in the Communications/Marketing Dept. in the past month or so compared to the long silences before.
I think their recent hiring of Jack Weinstein, a 40-yr. industry veteran of investment banking/business developmt/biopharma consulting has been a factor in more frequent & better PRs. You guys have to remember that Relief has been a very small biopharma of only 10 or so employees. They only just hired for 3 key positions - CMO, CFO, Developmt/Regulatory Consultant - in the past 2 mos.
They were just primarily medical scientists who are very limited in their marketing and business skills, much to the detriment of its shareholders.
The key takeaway of which Covid-19 Pts. this Therapeutic treats relative to Relief's Aviptadil is this:
{Bamlanivimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. A benefit of bamlanivimab treatment has not been shown in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.}
But it got EUA Approval b/c this Therapeutic's Trial has 400 Pts., which is more than 2x Relief's enrollment, and it showed a high degree of efficacy for keeping these Pts. out of the hospital or being put on oxygen based on Interim results.
That's some very good advice for those who are in panic-mode. Relief is a LONG play, and Traders on this board need to Really Understand what that means for them. Watching the stock price everyday isn't going to help any unless you plan to buy shares at a cheaper price.
I believe the recent Relief hires who are industry veterans & experts in Wall St. Banking & Finance, Healthcare Institutional Investors, FDA regulations, Clinical Trials are currently working behind-the-scenes to get Relief/NeuroRx's Aviptadil to the finish line as expeditiously as possible and to increase shareholder value with Institutional Investors, possible reverse-split and other strategies.
You don't read or communicate fine. Go back & read what you wrote in your reply, where you said "institutions don't freak out & sell", which has nothing to do with what I posted.
You don't seem to read well. I didn't say anything about Institutional Investors 'Selling'. What I said was that the new CFO is working on "attracting Institutional Investors to Relief", meaning to Invest in the company!
The Ask price is already down to .29 pre-market. We're in for some rough seas ahead, so hold on tight. But likely it'll be the night before the dawn.
That 90% figure is still not all that it seems 'coz it doesn't say how sick the vaccinated 10% who got Covid were, among other details which weren't revealed.
The recently-hired CFO with 40 yrs experience in healthcare finance/investment has been tasked with attracting institutional investors to Relief. Let's hope he's been successful in doing that job.
It's already been known for several mos. now.
Pfizer actually said that they can manufacture 20mill-40mill doses by 1Q2021. Don't know if that's possible.
The surge in cases here in CA are largely in So. Calif. where many people aren't following the Safety guidelines of wearing a mask, social-distancing and avoiding large gatherings.
However, No. Calif. has had a relatively very small number of cases/deaths compared to other areas.